The Role of data in Phar­ma­ceu­ti­cal Indus­try and clin­i­cal tri­als

Back­ground

Not all patients who are diag­nosed with Autoan­ti­bod­ies in Breast Can­cer Detec­tion (ABCD) may respond to treat­ment and drugs avail­able today. Their last alter­na­tive is to explore drugs and treat­ment in clin­i­cal tri­als. Unfor­tu­nate­ly, avail­abil­i­ty of such infor­ma­tion in a coher­ent sim­ple to under­stand plat­form is a lux­u­ry. Clin­i­cal tri­als are done when all avail­able treat­ments have proven unsuc­cess­ful yet the process of enrolling in a clin­i­cal tri­al can be expen­sive, time con­sum­ing and com­pli­cat­ed for the patients. High cost of research and devel­op­ment in drug design results in high­er drug prices and high­er insur­ance pre­mi­ums. The US gov­ern­ment esti­mates that as at May 2018, only 3% of can­cer patients are enrolled for clin­i­cal tri­als. How can clin­i­cal tri­als be made less expen­sive, effi­cient and more acces­si­ble to patients?

Datasets used

One of the rea­sons why clin­i­cal tri­als fail is due to data col­lec­tion process. A first step is access to curat­ed data­base of clin­i­cal tri­als where patients can direct­ly search based on cat­e­gories and loca­tion. In addi­tion, anonymised patient infor­ma­tion and drug analy­sis report can be viewed on the data mar­ket­place. Avail­abil­i­ty of this infor­ma­tion rather than oral rec­om­men­da­tion from health per­son­nel will increase the per­cent­age of patients involved in such clin­i­cal tri­als. The process even becomes more effi­cient when the Research team have dig­i­tal copies (not pdf or fax) of patient med­ical records and pre­vi­ous treat­ment reports. The Adva­neo data mar­ket­place has been devel­oped to address this.

Adva­neo Data Mar­ket­place

Among the numer­ous fea­tures of the data mar­ket­place of rel­e­vance to the health­care sec­tor espe­cial­ly clin­i­cal tri­als is ensur­ing secu­ri­ty and pri­va­cy while facil­i­tat­ing seam­less exchange of data to select­ed med­ical insti­tu­tions. The Adva­neo data mar­ket­place offers:



Secu­ri­ty and Pri­va­cy: No dataset will be stored on the mar­ket­place rather, ver­i­fied data end­points to where such infor­ma­tion can be obtained is pro­vid­ed in addi­tion to a stan­dard­ised descrip­tion of the dataset (meta­da­ta). The data provider (patient/hospital) main­tains the dataset with 100% data gov­er­nance.



Bro­ker Ser­vice: Sup­ple­men­tary infor­ma­tion such as dietary habits, activ­i­ty and sleep cycle can be inde­pen­dent­ly gath­ered by the patient using a vari­ety of smart­phone apps and wear­ables. This data which belongs to the patient can be shared freely or trad­ed by the patient. Our bro­ker ser­vice ensures this is done with no com­pli­cat­ed over­head on the data provider. Such datasets will pre­vent depen­dence on sub­jec­tive response dur­ing clin­i­cal tri­als.



Closed User Groups: The progress and final results of clin­i­cal tri­als can become trade secrets that should kept pri­vate to par­ties involved in the process. The data mar­ket­place pro­vides the option to cre­ate closed user groups. The exis­tence of such groups and mem­bers will remain incog­ni­to. More impor­tant­ly the meta­da­ta is only vis­i­ble by the mem­bers of the group and the dataset are exchange direct­ly between pairs.

Impact

The search for appro­pri­ate drugs to treat can­cer by using clin­i­cal tri­al analy­sis is cur­rent­ly a long expen­sive process. Col­la­tion and avail­abil­i­ty of high qual­i­ty datasets will be a sig­nif­i­cant step towards trans­form­ing the process. In addi­tion, the pos­si­bil­i­ties become end­less when machine learn­ing tools are applied to these datasets for patient to clin­i­cal tri­al match­ing, ear­ly anom­aly diag­no­sis and data dri­ven drug design process. The avail­abil­i­ty of data will also aid machine learn­ing appli­ca­tions in pre­ven­tion and ear­ly diag­no­sis of health pan­demics. In fact, deep learn­ing appli­ca­tions will con­tribute 3 bil­lion dol­lars to the health­care sec­tor by 2025. This will lead to sig­nif­i­cant reduc­tion in cost of health­care while cre­at­ing new busi­ness oppor­tu­ni­ties in the health­care sec­tor.

Phone.: 0211 8766910
Email:
Your Con­tact: Jür­gen Bret­feld